
According to Benzinga Pro, during Q4, Corcept Therapeutics (NASDAQ:CORT) earned $32.05 million, a 5.19% increase from the preceding quarter. Corcept Therapeutics also posted a total of $98.82 million in sales, a 2.8% increase since Q3. Corcept Therapeutics earned $30.47 million, and sales totaled $96.13 million in Q3.